
Oncology NEWS International
- Oncology NEWS International Vol 15 No 6
- Volume 15
- Issue 6
Phase I Trial of NPI-0052 Begins
Nereus Pharmaceuticals, Inc. has initiated a phase I trial of its novel, small molecule proteasome inhibitor, NPI-0052, in patients with solid tumors and lymphomas. The trial will enroll approximately 50 patients at two sites, M.D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center. NPI-0052 was discovered during the fermentation of Salinispora sp, a new class of Gram-positive marine bacteria, Nereus said in a press release.
SAN DIEGO, CalifNereus Pharmaceuticals, Inc. has initiated a phase I trial of its novel, small molecule proteasome inhibitor, NPI-0052, in patients with solid tumors and lymphomas. The trial will enroll approximately 50 patients at two sites, M.D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center. NPI-0052 was discovered during the fermentation of Salinispora sp, a new class of Gram-positive marine bacteria, Nereus said in a press release.
Articles in this issue
about 20 years ago
Triple-Negative Cancers More Common in Young Black Ptsabout 20 years ago
Artists Turn Flowers & Curves Into 'Forms' and 'Figures'about 20 years ago
Study to Examine Outcomes Disparities in Pediatric ALLabout 20 years ago
Thalidomide Has 'Changed the Paradigm' in Myeloma Rxabout 20 years ago
CA4P Gets Orphan Drug Statusabout 20 years ago
Testicular Ca Survivors at Increased Risk for CV Eventsabout 20 years ago
A Novel Brings a Cancer Research Laboratory to Lifeabout 20 years ago
NCCN Reveals New Venous Thromboembolism Guidelineabout 20 years ago
Lapatinib New Option for Metastatic HER2+ Breast Caabout 20 years ago
FDA Approves Dacogen for Treating All MDS Subtypes














































































